The global women's health market was valued at USD 35.02 billion in 2019 and is expected to reach USD 41.05 billion by 2027, growing at a CAGR of 3.2% during the forecast period. In 2019, North America led the market, holding a dominant share of 51.4%.

The increasing prevalence of women-specific health conditions, such as osteoporosis, breast cancer, and menopause, is a key driver of market growth. For example, the World Health Organization (WHO) reports that breast cancer is the most common cancer among women, affecting 2.1 million women annually and accounting for approximately 15% of all cancer-related deaths in women. Market participants are strengthening their positions in this growing sector through strategic collaborations, product launches, and awareness initiatives. As an example, in March 2020, Ziqitza Healthcare launched a Corporate Wellness Program aimed at helping female employees improve their productivity while managing their health effectively.

Tariff Impact Analysis for Women’s Health Market

**https://www.fortunebusinessinsights.com/industry-reports/women-s-health-market-101847**

List of Key Companies Profiled in the Women’s Health Market Report:

• Agile Therapeutics (New Jersey, USA)
• LUPIN (Mumbai, India)
• Merck & Co., Inc. (New Jersey, United States)
• Amgen Inc. (California, United States)
• Bayer AG (Leverkusen, Germany)
• AstraZeneca (Cambridge, UK)
• Eli Lilly and Company (Indiana, United States)
• Novartis AG (Basel, Switzerland)
• Pfizer Inc. (New York, United States)